Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event

The management of metastatic non-small cell lung cancer (NSCLC) has largely shifted over the past several decades from cytotoxic chemotherapy towards targeted therapy for patients with particular genetic driver mutations, such as epidermal growth factor receptor mutations and the abnormal fusion of...

Full description

Bibliographic Details
Main Authors: Evan Bryson, Suresh Ramalingam, Tyler Beardslee
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621920300235